灯盏花素联合依达拉奉治疗脑卒中后脑细胞损伤临床评价

Clinical Evaluation of Breviscapine Injection Combined with Edaravone in the Treatment of Patients with Brain Cell Injury After Stroke

目的探讨灯盏花素注射液联合依达拉奉注射液治疗脑卒中后脑细胞损伤的临床疗效及对患者血管内皮生长因子(VEGF)水平的影响。方法选取医院2016年9月至2019年9月收治的脑卒中后脑细胞损伤患者514例,按随机数字表法分为观察组和对照组,各257例。两组患者均予脑卒中的基础治疗,并予依达拉奉注射液静脉滴注,观察组患者加用灯盏花素注射液静脉滴注。两组患者均持续治疗4周。结果观察组总有效率为90.27%,显著高于对照组的81.71%(P <0.05);治疗后,观察组患者的美国国立卫生研究院卒中量表(NIHSS)评分及神经元特异性烯醇化酶(NSE)、高切全血黏度(HBV)、中切全血黏度(MBV)、低切全血黏度(LBV)水平均显著低于对照组,简易精神状态评价量表(MMSE)评分、日常生活活动量表(ADL)评分及VEGF、转化生长因子β1(TGF-β1)水平均显著高于对照组(P <0.05);治疗期间,观察组与对照组不良反应发生率相当(9.73%比6.61%,χ2=1.659,P=0.158> 0.05)。结论灯盏花素联合依达拉奉治疗脑卒中后脑细胞损伤效果显著,能减轻神经功能缺损程度,提高认知功能,上调VEGF和TGF-β1水平,降低NSE水平,改善血液流变学指标。

Objective To study the clinical effiaccy of breviscapine injection combined with edaravone for patients with brain cell injury after stroke and its effect on the level of vascular endothelial growth factor( VEGF).Methods A total of 514 patients with brain cell injury after stroke in the hospital from September 2016 to September 2019 were selected and divided into the observation group and control group according to random number table method,257 cases in each group.Both groups were treated with basic treatment of stroke;the control group received edaravone injection,and the observation group received breviscapine injection.Both groups were continuously treated for 4 weeks.Results The total effective rate of the observation group was 90.27%,which was significantly higher than 81.71% of the control group( P < 0.05).After treatment,the National Institutes of Health Stroke Scale( NIHSS) score,neuron-specific enolase( NSE),high-cut whole blood viscosity( HBV),mid-cut whole blood viscosity( MBV),low cut whole blood viscosity( LBV) level in the observation group were significantly lower than those of the control group,while the simple mental state evaluation scale,MMSE score,activity of daily living( ADL) score,VEGF,and transforming growth factor-β1( TGF-β1) levels were significant higher than those of the control group( P < 0.05);during the treatment,the observation group and the control group had the same incidence of adverse reactions( 9.73% vs.6.61%,χ2 = 1.659,P = 0.158 > 0.05).Conclusion Breviscapine injection combined with edaravone has a significant therapeutic effect for patients with brain cell injury after stroke,which can improve the degree of neurological deficit,improve the cognitive function,up regulate the level of VEGF and TGF-β1,reduce the level of NSE,improve the indexes of hemorheology of the patients.